Vanguard Fiduciary Trust
ENSC icon

Vanguard Fiduciary Trust’s Ensysce Biosciences ENSC Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,854
Closed -$12.9K – 4099
2026
Q1 		$12.9K Buy
+23,854
New +$15.1K ﹤0.01% 3985

Other funds holding ENSC

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $185M AUM 20.3% 1-Year Est. Return

Vanguard Fiduciary Trust's ENSC Position: Q2 2026 in Review

Vanguard Fiduciary Trust sold out of Ensysce Biosciences (ENSC) in Q2 2026, closing a stake of 23,854 shares — an estimated $12.9K sold.

Vanguard Fiduciary Trust first reported a position in ENSC in Q1 2026 and held it in 1 quarter. The position peaked at $12.9K in Q1 2026. 18 funds tracked by Wall St. Rank hold ENSC as of Q2 2026.

  • Vanguard Fiduciary Trust reported no remaining Ensysce Biosciences position as of Q2 2026 after selling out during the quarter.
  • Vanguard Fiduciary Trust sold 23,854 Ensysce Biosciences shares in Q2 2026, an estimated $12.9K.
  • Vanguard Fiduciary Trust first reported a position in Ensysce Biosciences in Q1 2026 and held it in 1 quarter.
  • Vanguard Fiduciary Trust's Ensysce Biosciences position peaked at $12.9K in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.